• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: CRYOLIFE, INC. HERO GRAFT; VASCULAR GRAFT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

CRYOLIFE, INC. HERO GRAFT; VASCULAR GRAFT Back to Search Results
Model Number HERO 1001
Device Problem Complete Blockage (1094)
Patient Problems Hyperplasia (1906); Thrombosis (2100)
Event Date 04/11/2015
Event Type  Injury  
Manufacturer Narrative
According to the report, "only heard information that there had been 3 revisions on patients who previously received a hero graft." additional information was received which indicated the hospital had "performed five hero graft implantations in five patients.We have performed five revisions in four patients." this report represents the third of four patients.According to the surgeons, "the fourth patient that received revision was a (b)(6) man.The initial operation was on [(b)(6) 2015], [lot numbers] hero 1001 h14vc051, [hero] 1002 h14av015, [hero] 1003 h14ak016.The revision was performed on [(b)(6) 2015].The cause was graft thrombosis.We were again left with the impression that the intimal hyperplasia at the titanium connector had caused the thrombosis." this medwatch report is submitted for hero 1001; however, all lots were investigated.The manufacturing records for lots h14vc051, h14av015, and h14ak016 were reviewed and it was confirmed that all records were controlled, available for review, and met all specifications per the device master record.A review was performed of the available information.At this time, the role of the hero graft in these revisions cannot be determined with the available information, although graft revision/replacement is an established treatment for arteriovenous (av) graft complications.Thrombosis is the most common cause of vascular access dysfunction.Thrombosis is a known potential complication of the hero graft and adequate precautions and warnings are provided in the instructions for use (ifu).The risk of thrombosis is influenced by compliance with hemodialysis schedule and patient medical history.For example, hypercoagulability states or inadequately maintained anticoagulation therapy could contribute to an increased risk of thrombosis.Precautions regarding inadequate anticoagulation are provided in the ifu.Medical history was not available for these cases of thrombosis/revision.For these 4 cases of thrombosis in 3 patients, the surgeon believed the thrombosis was "due to intimal hyperplasia at the titanium connector." operative notes for the original hero implant procedures and the revisions were not available; details on the exact revision performed in each case are therefore unknown.Samples were also not received and it cannot be determined if intimal hyperplasia was the cause of the thrombosis events.At this time, the cause of the intimal hyperplasia and the following thrombosis events are unknown as the details of the cases are largely unavailable.
 
Event Description
According to the report, "only heard information that there had been 3 revisions on patients who previously received a hero graft." additional information was received which indicated the hospital had "performed five hero graft implantations in five patients.We have performed five revisions in four patients." this report represents the third of four patients.According to the surgeons, "the fourth patient that received revision was a (b)(6) man.The initial operation was on [(b)(6) 2015], [lot numbers] hero 1001 h14vc051, [hero] 1002 h14av015, [hero] 1003 h14ak016.The revision was performed on [(b)(6) 2015].The cause was graft thrombosis.We were again left with the impression that the intimal hyperplasia at the titanium connector had caused the thrombosis." this medwatch report is submitted for hero 1001; however, all lots were investigated.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
HERO GRAFT
Type of Device
VASCULAR GRAFT
Manufacturer (Section D)
CRYOLIFE, INC.
1655 roberts blvd., nw
kennesaw GA 30144
Manufacturer (Section G)
CRYOLIFE, INC.
1655 roberts blvd., nw
kennesaw GA 30144
Manufacturer Contact
sandra o'reilly
1655 roberts blvd., nw
kennesaw, GA 30144
7704193355
MDR Report Key5017546
MDR Text Key23532853
Report Number1063481-2015-00171
Device Sequence Number1
Product Code DSY
Combination Product (y/n)N
Reporter Country CodeGM
PMA/PMN Number
K124039
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,foreig
Reporter Occupation Physician
Report Date 07/28/2015
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received08/20/2015
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Physician
Device Model NumberHERO 1001
Device Lot NumberH14VC051
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received07/28/2015
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Hospitalization; Other;
Patient Age60 YR
-
-